Efficacy of a bivalent killed whole-cell cholera vaccine over five years: a re-analysis of a cluster-randomized trial.
Halloran, M Elizabeth
Park, Jin Kyung
Clemens, John D
BMC Infect Dis
Springer Science and Business Media LLC
MetadataShow full item record
Fong, Y., Halloran, M. E., Park, J. K., Marks, F., Clemens, J. D., & Chao, D. L. (2018). Efficacy of a bivalent killed whole-cell cholera vaccine over five years: a re-analysis of a cluster-randomized trial.. BMC Infect Dis, 18 (1), 84. https://doi.org/10.1186/s12879-018-2981-4
BACKGROUND: Oral cholera vaccine (OCV) is a feasible tool to prevent or mitigate cholera outbreaks. A better understanding of the vaccine's efficacy among different age groups and how rapidly its protection wanes could help guide vaccination policy. METHODS: To estimate the level and duration of OCV efficacy, we re-analyzed data from a previously published cluster-randomized, double-blind, placebo controlled trial with five years of follow-up. We used a Cox proportional hazards model and modeled the potentially time-dependent effect of age categories on both vaccine efficacy and risk of infection in the placebo group. In addition, we investigated the impact of an outbreak period on model estimation. RESULTS: Vaccine efficacy was 38% (95% CI: -2%,62%) for those vaccinated from ages 1 to under 5 years old, 85% (95% CI: 67%,93%) for those 5 to under 15 years, and 69% (95% CI: 49%,81%) for those vaccinated at ages 15 years and older. Among adult vaccinees, efficacy did not appear to wane during the trial, but there was insufficient data to assess the waning of efficacy among child vaccinees. CONCLUSIONS: Through this re-analysis we were able to detect a statistically significant difference in OCV efficacy when the vaccine was administered to children under 5 years old vs. children 5 years and older. The estimated efficacies are more similar to the previously published analysis based on the first two years of follow-up than the analysis based on all five years. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT00289224.
Humans, Cholera, Cholera Vaccines, Treatment Outcome, Administration, Oral, Proportional Hazards Models, Risk Factors, Follow-Up Studies, Double-Blind Method, Placebo Effect, Adolescent, Adult, Child, Child, Preschool, Infant, Female, Male
External DOI: https://doi.org/10.1186/s12879-018-2981-4
This record's URL: https://www.repository.cam.ac.uk/handle/1810/284960
Attribution 4.0 International
Licence URL: https://creativecommons.org/licenses/by/4.0/